Vivos Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative, non-surgical, non-invasive, and non-pharmaceutical solutions for patients suffering from breathing-related sleep disorders, primarily obstructive sleep apnea (OSA) and snoring. The company's proprietary treatment protocol, known as The Vivos Method, utilizes customized oral appliances (such as the Complete Airway Repositioning and Expansion or CARE devices) to rehabilitate and expand the oral cavity and upper airway. Vivos holds first-of-its-kind FDA 510(k) clearances for treating mild-to-severe OSA in adults and moderate-to-severe pediatric sleep apnea.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pivoting the core business model away from the legacy dentist-focused VIP enrollment program toward direct contractual alliances with and acquisitions of medical sleep practices, sleep testing centers, and specialized medical providers.
Expected impact: Enables Vivos to capture higher-margin sleep disorder diagnostic and consultation revenues immediately, while driving downstream sales of its FDA-cleared OSA oral appliances directly to a larger patient volume.
Implementing cost-reduction measures targeting the legacy dental-focused distribution model, including a reduction in force and the restructuring or termination of legacy vendor relationships.
Expected impact: Estimated to yield approximately $4 million in annual expense savings on an annualized run-rate basis, advancing the company's goal of reaching cash flow positive operations.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquiring the operating assets of the largest operator of medical sleep centers in Nevada to complete Vivos' business model pivot, allowing the company to capture immediate diagnostic revenue and directly introduce its FDA-cleared OSA treatments to SCN's high volume of patients.
Financial impact: Contributed to a 70% year-over-year revenue increase in Q1 2026 (reaching $5.1 million), though integration and operating costs temporarily widened net losses.
Strategic Partnerships
Supports the formation and operation of AIM Florida, LLC, a physician-aligned MSO designed to expand access to integrated sleep apnea and insomnia diagnostics and treatments for cardiovascular disease patients in Florida.
Terms: Vivos expects to hold at least an 80% membership interest in AIM Florida, with SPCVA holding up to 20%. The initial Sleep Optimization Team is projected to generate over $6 million in annual revenue with contribution margins approaching 50% once fully deployed.